Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) has received a consensus rating of “Buy” from the thirteen research ...

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on ...

Needham & Company LLC reiterated their buy rating on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a report ...

Analysts have set 12-month price targets for Avidity Biosciences, revealing an average target of $66.31, a high estimate of ...

Avidity Biosciences (RNA) announced del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular dystrophy ...

In a report released today, Louise Chen from Scotiabank maintained a Buy rating on Avidity Biosciences (RNA – Research Report), with a price ...

After some earlier data sparked questions from analysts, Avidity Biosciences has released more data for its RNA-based ...

Avidity Biosciences Inc. says will submit an application for accelerated approval to the FDA for del-zota before the end of ...

The company plans to submit a Biologics Licence Application to the US Food and Drug Administration later in 2025 for its DMD ...

Just a few weeks after Avidity Biosciences made a stir with new data on its experimental therapy for Duchenne muscular dystrophy, the biotech has closed a public offering that raised an impressive ...

Stoke Therapeutics, Inc. is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen ...

The interim data found one child in the Duchenne trial produced more than double the amount of the protein needed to maintain ...